Meaningful Evidence
Nevro’s years of investment in clinical trials culminated in the SENZA-PDN study, the largest RCT to date evaluating SCS in PDN.
HFX for PDN
HFX for PDN
The most versatile SCS system is now also backed up by unmatched level 1 evidence for Painful Diabetic Neuropathy.
View Publication
Excellent Safety and Efficacy Profile
Within the SENZA-PDN, 10 kHz Therapy demonstrated exceptional outcomes across responder rates, pain relief, and even sensory response.
Direct Neural Inhibition With
10 kHz Therapy
Uniquely Possible With 10 kHz Therapy
Historically, PDN patients have struggled with a lack of treatment options when CMM fails. Now, 10 kHz Therapy and a unique mechanism of action offer new potential for relief.